Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 6/20 | 0.46 |
| ▸ | CALCA | P06881 | 10/20 | 0.44 |
| ▸ | ADM2 | Q7Z4H4 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12990698 | 0.90 | CALCRL (0.52) | CALCRLCALCAADM2 | |
| SCHEMBL12990699 | 0.81 | CALCA (0.49) | CALCRLCALCAADM2 | |
| SCHEMBL12628016 | 0.80 | CALCA (0.52) | CALCRLCALCA | |
| SCHEMBL13083797 | 0.78 | MAPT (0.51) | CALCRLCALCA | |
| SCHEMBL12990254 | 0.78 | CALCA (0.45) | CALCRLCALCA | |
| SCHEMBL12048962 | 0.77 | CALCRL (0.50) | CALCRLCALCAADM2 | |
| SCHEMBL12049385 | 0.77 | CALCA (0.55) | CALCRLCALCA | |
| SCHEMBL12049320 | 0.77 | CALCA (0.52) | CALCRLCALCA | |
| SCHEMBL12990708 | 0.76 | CALCA (0.47) | CALCRLCALCA | |
| SCHEMBL4501816 | 0.75 | CALCA (0.48) | CALCRLCALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954135-B1 | SPIROLACTAM ARYL CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| US-7851464-B2 | Spirolactam aryl CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851464-B2 | Spirolactam aryl CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20090247514-A1 | Spirolactam aryl cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2009-10-01 | — | — | US | disclosed |
| US-20090247514-A1 | Spirolactam aryl cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2009-10-01 | — | — | US | disclosed |
| WO-2007061677-A2 | SPIROLACTAM ARYL CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247514-A1 | Spirolactam aryl cgrp receptor antagonists | CALCRL, BDKRB1, CALCR | CALCRL 1/4885CALCA 5/4885ADM2 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.